Policy Updates   |   Position Statements

ASGCT Submits Comments on FDA Draft Guidance on Regenerative Medicine Expedited Programs

ASGCT Staff - February 19, 2018

ASGCT expressed appreciation for guidance titled, “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions," especially on the Regenerative Medicine Advanced Therapy (RMAT) designation and the inclusion of certain gene therapies in the eligibility for consideration for RMAT designation.

ASGCT leadership submitted comments to the FDA last week on the draft guidance titled, “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.” ASGCT expressed appreciation for guidance on these programs, especially on the Regenerative Medicine Advanced Therapy (RMAT) designation and the inclusion of certain gene therapies in the eligibility for consideration for RMAT designation.

The guidance identifies gene therapies, including genetically modified cells, which lead to a durable modification of cells or tissues, as eligible for RMAT designation.

A primary recommendation from ASGCT is to expand the eligibility for RMAT designation to all gene therapies to encourage the development of such therapies, which hold the potential to provide treatment for significant unmet need for multiple diseases.

Share This Page

Related Articles

Position Statements

A Statement of Solidarity

ASGCT Board of Directors - June 07, 2020
Policy Updates

FDA, NIH Issue Guidance on Conducting Clinical Trials During a Pandemic

ASGCT Staff - April 06, 2020
Policy Updates

ASGCT Applauds FDA's Gene Therapy Guidance Documents

Adora Ndu, PharmD, J.D. - February 03, 2020
Policy Updates

ASGCT Invited to Join USP as a Voting Member

ASGCT Staff - January 08, 2020